Background {#Sec1}
==========

Fatty acid oxidation (FAO) is a key metabolic pathway for maintaining energetic substrates used to maintain metabolic homeostasis. FAO is important for some high-energy-requiring organs and provides the main energy supply during prolonged fasting, febrile illness, cold exposure, or muscular exertion. The prime pathway for the degradation of fatty acids is mitochondrial fatty acid oxidation, which is composed of the uptake and activation of fatty acids, carnitine cycles, beta-oxidation cycle, and electron transfer \[[@CR1]\].

More than 15 distinct disorders have been described as affecting FAO; These include glutaric aciduria type 2, primary carnitine deficiency and deficiencies of carnitine palmitoyltransferase 1A (CPT1A), carnitine acylcarnitine translocase (CACT), very long chain acyl-CoA dehydrogenase (VLCAD), long chain hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein (LCHAD/MTP), medium chain acyl-CoA dehydrogenase (MCAD), medium/short chain hydroxyacyl-CoA dehydrogenase (M/SCHAD), and short chain acyl-CoA dehydrogenase (SCAD) \[[@CR2]--[@CR4]\].

After the introduction of newborn screening by tandem mass spectrometry analysis of acylcarnitines, the detection of FAO disorders (FAODs) has increased. The estimated combined incidence of all FAODs is 1 in 9000, which is calculated from reports out of Australia, Germany, and the USA, but it seems to be much lower in Asian countries \[[@CR5]\]. The estimated prevalence of long chain fatty acid oxidation disorders in Korea is 1 in 15,800, which is more frequently diagnosed following the introduction of tandem mass spectrometry newborn screening \[[@CR6]\].

FAODs present with a heterogeneous clinical phenotype at various ages of onset, from neonate to adulthood. The most severe form manifests with hypertrophic cardiomyopathy, hepatic encephalopathy, or severe hypoketotic hypoglycemia in the neonatal period or infancy. The less-severe, later-onset myopathic form is characterized by exercise-induced myopathy and rhabdomyolysis \[[@CR7], [@CR8]\].

The diagnosis of FAODs are based on the measurement of abnormal acylcarnitines and confirmed by enzyme assay or molecular analysis. Early identification of FAODs became possible using expanded newborn screening using tandem mass spectrometry, which measures acylcarnitine levels in dried blood spots. Identification of FAODs in newborn screening is very important because intervention in the presymptomatic period helps improve patient prognosis \[[@CR9]\].

In this respect, here we describe fourteen patients with diverse FAODs identified by newborn screening, and compare their clinical outcome and genetic characteristics with those of 8 patients diagnosed by symptomatic presentation. Our experience indicates the effectiveness of newborn screening for the early diagnosis of FAOD, especially in the presymptomatic period. However, careful observation and appropriate management is warranted to improve the clinical outcome of the affected patients.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

A total of fourteen patients were diagnosed with FAODs by newborn screening between May 2002 and February 2016 at the department of Medical Genetics, Asan Medical Center Children's Hospital, Seoul, Korea. Clinical features of these patients were compared with nine FAOD patients identified by symptomatic presentation, including rhabdomyolysis, cardiomyopathy, or developmental delay.

The Institutional Review Board at Asan Medical Center approved this study. Appropriate written informed consent was obtained from the parents of all participants.

### Methods {#Sec4}

Presenting manifestations, biochemical findings including plasma acylcarnitines, molecular analysis, and clinical course of each patient were reviewed retrospectively.

All patients diagnosed by newborn screening tests were referred to our department due to abnormal newborn screening results. Dried blood spot samples were obtained at the hospital where the patients were born and tandem mass spectrometry analysis was performed at commercial biochemical laboratories. Newborns with abnormal initial screening result were requested for repeated tandem mass spectrometry. If a second screening results were still exceeding the cut off value, molecular genetic analyses was performed and the diagnosis of FAOD was confirmed after receiving a positive confirmation test.

Acylcarnitine was measured by Liquid Chromatography-Tandem Mass Spectrometry, as previously described \[[@CR6]\]. Genomic DNA was isolated from peripheral blood leukocytes. PCR was performed for all coding exons and exon--intron boundaries of *SLC22A5* for primary carnitine deficiency, *CPT1A* for CPT1A deficiency, *ACADVL* for VLCAD deficiency, *HADHA* and *HADHB* for LCHAD/MTP deficiencies, *ACADM* for MCAD deficiency, and *ACADS* for SCAD deficiency. Direct sequencing was performed on a ABI 3130 genetic analyzer (Applied Biosystems, Foster City, CA, USA) using a BigDye Terminator cycle sequencing kit (Applied Biosystems). In silico prediction analyses were performed for novel missense and splicing variants, using PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2>) and SIFT (<http://sift.jcvi.org>).

Results {#Sec5}
=======

Clinical characteristics of patients with FAODs identified by newborn screening {#Sec6}
-------------------------------------------------------------------------------

FAODs were identified in 14 patients by newborn screening: VLCAD deficiency (5 patients), MCAD deficiency (5 patients), primary carnitine deficiency (1 patient), CPT1A deficiency (1 patient), LCHAD/MTP deficiencies (1 patient), and SCAD deficiency (1 patient). Newborn screening using tandem mass spectrometry was performed at 3.2 ± 0.2 days after birth and the diagnosis of FAOD was confirmed by molecular genetic analyses at the mean age of 54.7 ± 40.8 days (range: 16--153 days). Plasma C14:1 and C14:2 were elevated in VLCAD deficiency, C14OH, C16OH and C18:1OH levels in LCHAD/MTP deficiencies, C6 and C8 in MCAD deficiency, C2 and C4 in SCAD deficiency, and C0/(C16 + C18) in CPT1A deficiency. C0 level was markedly decreased in primary carnitine deficiency.

Molecular characteristics of patients with FAODs identified by newborn screening {#Sec7}
--------------------------------------------------------------------------------

Germline mutations of the gene responsible for each FAOD were identified in 90% of alleles (9 out of 10 alleles) in VLCAD deficiency, 90% (9 out of 10 alleles) in MCAD deficiency, 100% (2 out of 2 alleles) in LCHAD/MTP, primary carnitine, CPT1A, and SCAD deficiencies (Table [1](#Tab1){ref-type="table"}). In VLCAD deficiency, 5 out of 7 mutations were novel mutations, c.\[104_105ins10\] (p.\[Pro35fs\*27\]), c.\[104_105ins5\] (p.\[Pro35fs\*25\]), c.\[103_112dup\] (p.\[Arg38Profs\*26\]), c.\[996_997ins(T)\] (p.\[Ala333Cysfs\*26\]), and c.\[552C \> G\] (p.\[Ile184Met\])). Two novel mutations, c.\[748G \> T\] (p.\[Val250Leu\]) and c.\[1015C \> T\] (p.\[Arg339Ter\]), were detected in CPT1A deficiency. All other mutations were previously reported (Table [1](#Tab1){ref-type="table"}) \[[@CR10]--[@CR20]\].Table 1Clinical, biochemical, and genetic characteristics of patients with fatty acid oxidation disorders diagnosed by newborn screeningNoAge at diagnosisAge at last follow-upPhenotypeAcylcarnitineGeneAllele 1Allele 2SampleElevated acylcarnitine (value)Very long chain acyl-CoA dehydrogenase deficiency139 days3.7 yearsrecurrent rhabdomyolysis and hypertrophic cardiomyopathy after 7 months oldDBSC14 (2.504 μM; ref., 0.006--0.166), C14:1 (1.097 μM; ref., 0.006--0.166)*ACADVL*c.\[104_105ins10\] (p.\[P35fs\*27\]) ^a^c.\[104_105ins5\] (p.\[P35fs\*25\]) ^a^233 days5.8 yearsrecurrent rhabdomyolysis after 11 monthsDBSC14:1 (n.a.), C14 (n.a.), C14:2 (n.a.)*ACADVL*c.\[1349G \> A\] (p.\[R450H\])c.\[1349G \> A\] (p.\[R450H\])325 days10 monthshypertrophic cardiomyopathyDBSC14:2 (0.581 μM; ref., 0.006--0.166), C14:1 (1.391 μM; ref., 0.034--0.599)*ACADVL*c.\[103_112dup\] (p.\[R38P\*26\]) ^a^c.\[1532G \> A\] (p.\[R511Q\])449 days3.3 years1 episode of rhabdomyolysisDBSC14:1 (6.62 μM; ref., \<  0.85)*ACADVL*c.\[996_997ins(T)\] (p.\[A333C\*26\]) ^a^c.\[552C \> G\] (p.\[I184M\]) ^a^548 days2.0 yearsasymptomaticPlasmaC14 (0.184 μmol/L; ref., \<  0.15), C14:2 (0.215 μmol/L; ref., \<  0.13)*ACADVL*c.\[1349G \> A\] (p.\[R450H\])?Medium chain acyl-CoA dehydrogenase deficiency616 days4.5 yearsasymptomaticDBSC8 (0.68 μM; ref., \<  0.31)*ACADM*c.\[617G \> A\] (p.\[R206H\])c.\[1189 T \> A\] (p.\[Y397N\])736 days3.5 yearsasymptomaticDBSC6 (n.a.), C8 (n.a.), C10:1 (n.a.), C10 (n.a.)*ACADM*c.\[1085G \> A\] (p.\[G362E\])c.\[1189 T \> A\] (p.\[Y397N\])851 days6.9 yearsasymptomaticDBSC6 (0.46 μM; ref., \<  0.22), C8 (1.66 μM; ref., \< 0.35)*ACADM*c.\[449_452del\] (p.\[Y150Rfs\*4\])c.\[1189 T \> A\] (p.\[Y397N\])956 days1.4 yearsasymptomaticDBSC8 (2.98 μM; ref., \<  0.37), C10:1 (0.58 μM; ref., \<  0.40)*ACADM*c.\[449_452del\] (p.\[Y150Rfs\*4\])c.\[1085G \> A\] (p.\[G362E\])10153 days1.4 yearsasymptomaticPlasmaC6 (0.868 μmol/L; ref., \< 0.18), C8 (5.067 μmol/L; ref., \< 0.27), C10:1 (1.387 μmol/L; ref., \< 0.46)*ACADM*c.\[1189 T \> A\] (p.\[Y397N\])?Primary carnitine deficiency1153 days3.2 yearsmild CK elevation, normal developmentPlasmaC0 (4.1 μmol/L; ref., 12--46), Total carnitine (6.1 μmol/L; ref., 19--59)*SLC22A5*c.\[396G \> A\] (p.\[W132\*\])c.\[1400C \> G\] (p.\[S467C\])Carnitine palmitoyltransferase 1A deficiency1241 days5 monthsnormal developmentPlasmaC0 (80.839 μmol/L; ref., \< 62.10), C0/(C16 + C18) (123.5)*CPT1A*c.\[748G \> T\] (p.V250 L) ^a^c.\[1015C \> T\] (p.\[R399\*\]) ^a^Long chain hydroxyacyl-CoA dehydrogenase/mitochondrial trifunctional protein deficiencies1326 daysFamily history of sibling who died of lactic acidemia during the neonatal period. Died at age 49DBSC16OH (n.a.), C16OH/C16 (n.a.), C18:1OH (n.a.), C14 (n.a.), C14OH (n.a.)*HADHA*c.\[1689 + 2 T \> G\] (deletion of exon 16)c.\[1689 + 2 T \> G\] (deletion of exon 16)Short chain acyl-CoA dehydrogenase deficiency14141 days5 monthsasymptomaticPlasmaC4 (4.51 μmol/L; ref., \< 1.06)*ACADS*c.\[164C \> T\] (p.\[P55L\])c.\[1041A \> G\] (p.\[E344G\])^a^indicates novel mutations. *DBS* dried blood spot samples, *n.a*. not available

Clinical outcomes of patients with FAODs identified by newborn screening {#Sec8}
------------------------------------------------------------------------

The mean age at last follow-up for the 14 patients was 2.5 ± 2.0 years (range: 49 days--6.5 years). All patients had been educated to avoid prolonged fasting. Medium chain triglyceride diets with long chain fat restriction were recommended in the 5 patients with VLCAD deficiency and 1 patient with LCHAD/MTP deficiency. L-carnitine was given to 5 patients with MCAD deficiency even though the carnitine levels were within normal range, 1 patient with primary carnitine deficiency, and 1 patient with CPT1A deficiency.

Significant clinical manifestations that required emergency management were noted in 4 patients with VLCAD deficiency or LCHAD/MTP deficiency: recurrent rhabdomyolysis (2 patients), hypertrophic cardiomyopathy (2 patients), or sudden infantile death (1 patient). The remaining 2 patients with VLCAD deficiency and all patients with MCAD deficiency, SCAD deficiency, primary carnitine deficiency, or CPT1A deficiency were free of a metabolic crisis during the follow-up period. Additionally, the 13 surviving patients showed normal development without any neurologic deficit during the follow-up period (Table [1](#Tab1){ref-type="table"}).

Molecular and clinical characteristics of patients with FAODs identified by symptomatic presentation {#Sec9}
----------------------------------------------------------------------------------------------------

During the same study period, a total of 8 patients were diagnosed with FAODs by symptomatic presentation (Table [2](#Tab2){ref-type="table"}).Table 2Clinical, biochemical, and genetic characteristics of patients with fatty acid oxidation disorders diagnosed by clinical signs and symptomsNoAge at diagnosisAge at last follow-upPhenotypeAcylcarnitineGeneAllele 1Allele 2SampleElevated acylcarnitine (value)Long chain hydroxyacyl-CoA dehydrogenase/mitochondrial trifunctional protein deficiencies12.7 years11.3 yearsRecurrent rhabdomyolysis, sensorimotor polyneuropathy, difficulty running and climbing stairsDBSC10OH (n.a.), C18OH (n.a.)*HADHB*c.\[340A \> G\]\
(p. \[N114D\])c.\[739C \> T\] (p.\[R247C\])22.1 years11.9 yearsRecurrent rhabdomyolysis, sensorimotor polyneuropathy, difficulty running, positive Gowers' signDBSC10 (n.a.), C12 (n.a.), C14:1 (n.a.), C14OH (n.a.), C16OH (n.a.), C18:1OH (n.a.)*HADHB*c.\[340A \> G\]\
(p. \[N114D\])c.\[919A \> G\] (p.\[N307D\])34.8 years6.8 yearsRecurrent rhabdomyolysis, sensorimotor polyneuropathy, difficulty runningDBSC14OH (n.a.), C16OH (n.a.), C18OH (n.a.), C18:1OH (n.a.)*HADHB*c.\[340A \> G\]\
(p. \[N114D\])c.\[1148C \> T\] (p.\[S383 L\])410.6 years23.3 yearsRecurrent rhabdomyolysis, sensorimotor polyneuropathy, walk with assistanceDBSC14OH (0.156 μM; ref., 0.003--0.87), C16OH (0.228 μM; ref., 0.003--0.083), C18OH (0.072 μM; ref., 0.003--0.055)*HADHB*c.\[919A \> G\]\
(p.\[N307D\])c.\[1165A \> G\] (p.\[N389D\])51 day--Severe cardiomyopathy at first day of life. Died of lactic acidosis at 4 days oldDBSC16OH, (0.86 μM; ref., \< 0.15), C18OH (0.33 μM; ref., \< 0.1), C18:1OH (0.48 μM; ref., \< 0.08), C14:1 (0.66 μM; ref., \< 0.35), C14 (1.35 μM; ref., \< 0.86), C16:1 (0.54 μM; ref., \< 0.25)*HADHA*c.\[1793_1974del\]\
(p.\[H598Rfs\*33\])c.\[1793_1974del\] (p.\[H598Rfs\*33\])65 days--Presented with tachypnea and metabolic acidosis at 5 days old. Died at 9 days old due to cardiomyopathyDBSC14 (n.a.), C14OH (n.a.), C16OH (n.a.), C18OH (n.a.), C18:1OH (n.a.)*HADHB*c.\[1136A \> G\]\
(p.\[H379R\])c.\[1211dup\] (p.\[G404 fs\*2\]) ^a^Very long chain acyl-CoA dehydrogenase deficiency72 months3.9 yearsHypertrophic cardiomyopathy, recurrent rhabdomyolysisDBSC14:1 (n.a.), C14 (n.a.)*ACADVL*c.\[997_998ins(T)\]\
(p.\[A333\*\]) ^a^c.\[1770_1773del\] (p.\[S590\*\]) ^a^Carnitine palmitoyltransferase 1A deficiency833 months6.8 yearsRecurrent hepatic failure, nephromegaly, hemolytic anemia, rhabomyolysis, developmental delayPlasmaC0 (68.86 μmol/L; ref., \< 62.10),\
C0/(C16 + C18) (1639)*CPT1A*c.\[837_838insT\]\
(p.\[I279\*\])c.\[947G \> A\] (p.\[R316Q\])^a^indicates novel mutations. *DBS* dried blood spot samples, *n.a*. not available

One patient was diagnosed with VLCAD deficiency due to hypertrophic cardiomyopathy and rhabdomyolysis at the age of 2 months. This patient had two novel frameshift mutations in the *ACADVL* gene (p.A333fs and p.S590 fs). During the follow-up period of 3.5 years, this patient suffered from recurrent rhabdomyolysis and cardiomyopathy. LCHAD/MTP deficiencies were detected by cardiomyopathy with severe lactic acidosis at 1--5 days after birth (2 patients) and recurrent rhabdomyolysis at the median age of 9--48 months (4 patients). *HAHDA* or *HAHDB* mutations were identified in all six patients, including one novel mutation, c.\[1211dup\] (p.\[G404 fs\*2\]). During the median follow-up period of 5.3 years (range: 4 days--12.7 years), the two patients with cardiomyopathy died at ages of 4 days and 9 days. The remaining four patients experienced recurrent rhabdomyolysis and sensorimotor polyneuropathy. No patient developed pigmentary retinopathy during follow-up. No patient was identified with MCAD or primary carnitine deficiency by symptomatic presentation during the study period.

One patient with CPT1A deficiency was identified by recurrent hepatopathy, nephromegaly, rhabdomyolysis, and hemolytic anemia \[[@CR21]\]. Plasma acylcarnitine analysis revealed elevated free carnitine and ratio of free carnitine to C16 + C18. Compound heterozygous pathogenic mutations were identified in the *CPT1A* gene. Recurrent hepatic failure and intellectual disability was shown during 6.6 years of follow-up. At the age of 7, the patient's intelligence quotient (IQ) was less than 35 and Korean Childhood Autism Rating Scale (K-CARS) score was 44, suggesting severe intellectual disability and severe autism.

Discussion {#Sec10}
==========

The current study described the clinical and genetic features of 14 patients with FAODs identified by newborn screening, compared to those of 8 patients diagnosed with FAODs based on their symptomatic presentations.

The results of our current study indicate some important findings. Newborn screening helped to identify the broad spectrum of FAODs compared to FAODs with symptomatic presentation. These findings were comparable to previous reports regarding the newborn screening program \[[@CR8], [@CR22]\]. In addition, the relative frequency of each FAOD was reflected; VLCAD, LCHAD/MTP, and MCAD deficiencies were common FAODs identified by newborn screening. Alternatively, other FAODs, including primary carnitine deficiency, CPT1A or SCAD deficiencies, were identified in a small number of patients. Of note, VLCAD or LCHAD/MTP deficiencies were the most common among the FAODs identified either by newborn screening or by symptomatic presentation, whereas all patients with another common FAOD, MCAD deficiency, were identified by newborn screening, as symptomatic presentation of MCAD deficiency is expected to be very rare.

The purpose of newborn screening is to identify patients with inborn metabolic disorders in their presymptomatic period and intervene to prevent a metabolic crisis and improve their clinical outcome. In our current study, a fair outcome was observed in the patients with MCAD, CPT1A or primary carnitine deficiency identified by newborn screening. However, clinical outcomes were not significantly different among patients with long-chain FAODs, including VLCAD deficiency and LCHAD/MTP deficiencies identified either by newborn screening or by symptomatic presentation; most long-chain FAOD patients developed recurrent rhabdomyolysis and hypertrophic cardiomyopathy regardless of presymptomatic management.

The difference in outcomes among patients with FAODs appears to be related to disease characteristics and pathogenic effect of the mutations in addition to the mode of identification. In VLCAD or LCHAD/MTP deficiencies, patients identified by newborn screening experience a broad spectrum of severity even though the majority of patients were asymptomatic at diagnosis; symptoms develop in some patients even before newborn screening results were available, or some patients may remain asymptomatic through the long-term follow-up period \[[@CR23]--[@CR25]\]. Most of our patients with VLCAD or LCHAD/MTP deficiencies (4 out of 6) experienced recurrent rhabdomyolysis or severe cardiomyopathy. These severe phenotypes are related to complete inactivating or null alleles \[[@CR25]--[@CR28]\]. This correlation became more meaningful when the phenotype-genotype correlation was evaluated in all patients with VLCAD or LCHAD/MTP deficiencies, irrespective of the mode of identification. Seven patients with severe types of mutations, such as frameshift, nonsense, or splicing mutations, experienced severe phenotypes. Particularly, early death from severe cardiomyopathy was noted in 3 patients with severe mutations in LCHAD/MTP deficiencies. On the other hand, patients with missense mutations only either remained asymptomatic or experienced milder phenotypes (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).

As a long-term complication, peripheral polyneuropathy developed in four patients with LCHAD/MTP deficiencies, which has been reported in up to 80% of cases. In addition, pigmentary retinopathy develops in up 15--30% of patients \[[@CR29], [@CR30]\]. The mechanism responsible for these complications is not fully understood, although accumulation of 3-hydroxy fatty acid intermediate may be responsible \[[@CR8]\]. Because the follow-up period was short for the patients in our current report, observation for these long-term complications is necessary.

The benign clinical course of MCAD deficiency can also be explained in part by the mutation type; most of the mutations were missense and only a small proportion of severe mutations such as frame-shift were noted. However, a life-long follow-up evaluation is required for patients with MCAD deficiency, considering the development of late-onset metabolic episodes. Between 3 and 24 months of age, patients may experience hypoketotic hypoglycemia, vomiting, lethargy, encephalopathy during febrile illness, or prolonged fasting. Sudden unexplained death may be the first presentation of MCAD deficiency \[[@CR31], [@CR32]\]. Even some adult patients may suffer from rhabdomyolysis, hepatic failure, encephalopathy or cardiac arrest triggered by alcohol consumption, pregnancy, or prolonged fasting \[[@CR9], [@CR33]\].

SCAD deficiency has also been classified as a benign condition because most of the newborns with SCAD deficiency as identified by newborn screening do not develop a clinical phenotype without any medical intervention. There exist controversies whether SCAD deficiency is benign biochemical phenotype, a clinical disorder with incomplete penetrance, or a clinically relevant part of multi-factorial or a multi-genetic disorder \[[@CR34], [@CR35]\]. Previously, some patients reported as having severe developmental delay, dysmorphic features and epilepsy, which would have been attributed to unknown genetic defects rather than to SCAD deficiency.

The CPT1A deficiency patient identified by newborn screening harbor heterozygous of two novel mutations. The patient remained asymptomatic during follow-up period, which was relatively short considering that CPT1A deficiency patients usually present by the age of 2 years \[[@CR36]\]. The major manifestation of CPT1A deficiency is hepatic encephalopathy followed by febrile illness or prolonged fasting \[[@CR21]\]. Even for a patient with neonatal presymptomatic presentation, late-onset hepatic failure develops, requiring lifelong evaluation. There exists a possibility that the novel missense mutation may not be deleterious, yet longer follow-up is needed in our patient in case of developing the symptomatic manifestations.

Conclusions {#Sec11}
===========

Newborn screening for FAODs revealed the relative frequency of each disease subtype and their general clinical characteristics. This screening helped to reduce the mortality and morbidity of each patient with FAODs, but their broad spectrum of disease severity was also encountered regardless the mode of diagnosis, which was explained in part by their respective genotype. Careful, life-long observation of patients with FAODs is required to improve clinical outcome.
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